Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 777

1.

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.

Qian X, Dimopoulos MA, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel KC, Ocio EM, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A.

Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485915. [Epub ahead of print]

PMID:
30068263
2.

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.

Goussia A, Simou N, Zagouri F, Manousou K, Lazaridis G, Gogas H, Koutras A, Sotiropoulou M, Pentheroudakis G, Bafaloukos D, Markopoulos C, Patsea H, Christodoulou C, Papakostas P, Zaramboukas T, Samantas E, Kosmidis P, Venizelos V, Karanikiotis C, Papatsibas G, Xepapadakis G, Kalogeras KT, Bamia C, Dimopoulos MA, Malamou-Mitsi V, Fountzilas G, Batistatou A.

PLoS One. 2018 Jul 31;13(7):e0200302. doi: 10.1371/journal.pone.0200302. eCollection 2018.

3.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Jul 23. doi: 10.1038/s41375-018-0209-7. [Epub ahead of print] Review.

PMID:
30038381
4.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Jul 20. doi: 10.1111/ejh.13147. [Epub ahead of print]

PMID:
30027641
5.

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.

Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

Leukemia. 2018 Jul 19. doi: 10.1038/s41375-018-0197-7. [Epub ahead of print]

PMID:
30026568
6.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Jul 5. doi: 10.1093/annonc/mdy146. [Epub ahead of print] No abstract available.

PMID:
29982402
7.

Managing myeloma with limited resources in the era of novel drugs.

Dimopoulos MA, Kastritis E.

Leuk Lymphoma. 2018 Jul 3:1-2. doi: 10.1080/10428194.2018.1476692. [Epub ahead of print] No abstract available.

PMID:
29966456
8.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.

PMID:
29958569
9.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Apr 25. doi: 10.1038/s41375-018-0142-9. [Epub ahead of print] Review.

PMID:
29880892
10.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK.

Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

PMID:
29866475
11.

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, Dimopoulos MA.

Ann Transl Med. 2018 Apr;6(8):144. doi: 10.21037/atm.2018.02.07. Review.

12.

Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA.

Ann Transl Med. 2018 Apr;6(8):143. doi: 10.21037/atm.2018.02.18. Review.

13.

Treating ALK-positive non-small cell lung cancer.

Ziogas DC, Tsiara A, Tsironis G, Lykka M, Liontos M, Bamias A, Dimopoulos MA.

Ann Transl Med. 2018 Apr;6(8):141. doi: 10.21037/atm.2017.11.34. Review.

14.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

PMID:
29856685
15.

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3. No abstract available.

16.

Optimizing therapy in bortezomib-exposed patients with multiple myeloma.

Migkou M, Gavriatopoulou M, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2018 Jun;11(6):463-469. doi: 10.1080/17474086.2018.1479637. Epub 2018 May 28.

PMID:
29788798
17.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

18.

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2018 May 11;8(5):42. doi: 10.1038/s41408-018-0075-6.

19.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
20.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 May 2. doi: 10.1038/s41375-018-0040-1. [Epub ahead of print] Review.

21.

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.

Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S.

Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.

22.

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.

Papanagnou ED, Terpos E, Kastritis E, Papassideri IS, Tsitsilonis OE, Dimopoulos MA, Trougakos IP.

Oncotarget. 2018 Apr 3;9(25):17797-17809. doi: 10.18632/oncotarget.24882. eCollection 2018 Apr 3.

23.

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.

Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, Dimopoulos MA, Terpos E.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31.

PMID:
29685422
24.

How We Manage Patients with Plasmacytomas.

Fotiou D, Dimopoulos MA, Kastritis E.

Curr Hematol Malig Rep. 2018 Jun;13(3):227-235. doi: 10.1007/s11899-018-0452-z. Review.

PMID:
29667156
25.

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia.

Gavriatopoulou M, Kastritis E, Dimopoulos MA.

Oncotarget. 2017 Dec 18;9(16):12536-12537. doi: 10.18632/oncotarget.23400. eCollection 2018 Feb 27. No abstract available.

26.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

27.

Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies.

Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Tsilimigras DI, Dimopoulos MA.

Int J Cancer. 2018 Aug 1;143(3):486-495. doi: 10.1002/ijc.31330. Epub 2018 Mar 30.

PMID:
29460427
28.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.

Dimopoulos MA, Kaufman JL, White D, Cook G, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):163-173.e6. doi: 10.1016/j.clml.2017.12.011. Epub 2018 Jan 5.

29.

Denosumab for myeloma bone disease: ready for prime time?

Dimopoulos MA, Kastritis E.

Lancet Oncol. 2018 Mar;19(3):277-278. doi: 10.1016/S1470-2045(18)30075-5. Epub 2018 Feb 9. No abstract available.

PMID:
29429916
30.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
31.

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK.

J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.

PMID:
29341834
32.

Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature review.

Kouerinis IA, Tolia M, Zagouri F, Nikolaou M, Tsoukalas N, Kyrgias G, Dimopoulos MA, Vlachopoulos C, Karathanassis I, Zoubouli CK, Kokakis I, Kouloulias V, Triantafillou K.

J BUON. 2017 Nov-Dec;22(6):1385-1389.

PMID:
29332327
33.

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA.

Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4. Review.

34.

Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply.

Dimopoulos MA, Kimball AS.

Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8. No abstract available.

PMID:
29304357
35.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E.

Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28.

36.

Disease control should be the goal of therapy for WM patients.

Kastritis E, Dimopoulos MA.

Blood Adv. 2017 Nov 28;1(25):2483-2485. doi: 10.1182/bloodadvances.2017005645. eCollection 2017 Nov 28.

37.

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.

Tsakiri EN, Terpos E, Papanagnou ED, Kastritis E, Brieudes V, Halabalaki M, Bagratuni T, Florea BI, Overkleeft HS, Scorrano L, Skaltsounis AL, Dimopoulos MA, Trougakos IP.

Sci Rep. 2017 Dec 19;7(1):17802. doi: 10.1038/s41598-017-17596-4.

38.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

39.

Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity.

Anastasiou M, Oikonomou E, Zagouri F, Siasos G, Antonopoulos AS, Psaltopoulou T, Bamias A, Dimopoulos MA, Tousoulis D.

J Am Coll Cardiol. 2017 Dec 19;70(24):3072. doi: 10.1016/j.jacc.2017.09.1140. No abstract available.

PMID:
29241496
40.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

PMID:
29231133
41.

Rare manifestations of extramedullary myeloma: testicular plasmacytomas.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Eleftherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2018 Aug;59(8):2002-2004. doi: 10.1080/10428194.2017.1410887. Epub 2017 Dec 7. No abstract available.

PMID:
29214871
42.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S.

Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017.

43.

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.

Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA.

Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. No abstract available.

PMID:
29167176
44.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

45.

An overview of the role of carfilzomib in the treatment of multiple myeloma.

Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA.

Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20. Review.

PMID:
29134824
46.

Mechanisms of bone destruction in multiple myeloma.

Terpos E, Christoulas D, Gavriatopoulou M, Dimopoulos MA.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12761. Epub 2017 Sep 21. Review.

PMID:
28940410
47.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA.

Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22.

PMID:
28937327
48.

Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies.

Sergentanis TN, Psaltopoulou T, Ntanasis-Stathopoulos I, Liaskas A, Tzanninis IG, Dimopoulos MA.

Leuk Lymphoma. 2018 Feb;59(2):434-447. doi: 10.1080/10428194.2017.1339873. Epub 2017 Aug 28. Review.

PMID:
28847196
49.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

PMID:
28843768
50.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

Supplemental Content

Loading ...
Support Center